Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Stemline Therapeutic (STML)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
27.8% Return Seen to Date on SmarTrend Stemline Therape Call (STML)

SmarTrend identified an Uptrend for Stemline Therape (NASDAQ:STML) on January 18th, 2019 at $10.45. In approximately 2 months, Stemline Therape has returned 27.81% as of today's recent price of $13.35....

STML : 12.36 (-6.79%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CCXI , STML , CYTK , NBIX , DVAX )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CYTK : 8.77 (-0.79%)
STML : 12.36 (-6.79%)
CCXI : 10.91 (+3.90%)
Stemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH Conference

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that Ivan Bergstein,...

STML : 12.36 (-6.79%)
Stemline Therapeutics: 4Q Earnings Snapshot

NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Friday reported a loss of $26.6 million in its fourth quarter.

STML : 12.36 (-6.79%)
Stemline Therapeutics Reports Fourth Quarter 2018 Financial Results

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today financial results...

STML : 12.36 (-6.79%)
Uptrend Call Working As Stemline Therape Stock Rises 29.3% (STML)

SmarTrend identified an Uptrend for Stemline Therape (NASDAQ:STML) on January 18th, 2019 at $10.45. In approximately 2 months, Stemline Therape has returned 29.34% as of today's recent price of $13.51....

STML : 12.36 (-6.79%)
Stemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that it has exclusively...

STML : 12.36 (-6.79%)
Stemline Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein,...

STML : 12.36 (-6.79%)
Shares of Stemline Therape Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (STML , ALNY , SRPT , ESPR , PTCT )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

SRPT : 122.25 (-3.48%)
STML : 12.36 (-6.79%)
ALNY : 84.69 (-6.67%)
Watch for Stemline Therape to Potentially Pullback After Gaining 4.29% Yesterday

Stemline Therape (NASDAQ:STML) traded in a range yesterday that spanned from a low of $11.42 to a high of $11.90. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high...

STML : 12.36 (-6.79%)
Consolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Marriott International (NASDAQ:MAR),...

STML : 12.36 (-6.79%)
CVGW : 81.64 (-1.96%)
MAR : 124.50 (-0.45%)
KNSL : 68.19 (-0.90%)
FLDM : 13.59 (-4.90%)
GSBD : 20.72 (-0.38%)
Stemline Therapeutics Closes $92 Million Public Offering of Common Stock

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced...

JPM : 99.75 (-3.03%)
STML : 12.36 (-6.79%)
Stemline Therapeutics (STML) in Focus: Stock Moves 9.5% Higher

Stemline Therapeutics (STML) shares rose nearly 10% in the last trading session, amid huge volumes.

ACIU : 4.79 (+6.44%)
STML : 12.36 (-6.79%)
Stemline Therape Has Returned 32.6% Since SmarTrend Recommendation (STML)

SmarTrend identified a Downtrend for Stemline Therape (NASDAQ:STML) on October 15th, 2018 at $14.75. In approximately 3 months, Stemline Therape has returned 32.61% as of today's recent price of $9.94....

STML : 12.36 (-6.79%)
Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced...

JPM : 99.75 (-3.03%)
STML : 12.36 (-6.79%)
Stemline Therapeutics Announces Proposed Public Offering of Common Stock

Stemline Therapeutics, Inc. (Nasdaq:STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced...

JPM : 99.75 (-3.03%)
STML : 12.36 (-6.79%)
Look for Shares of Stemline Therape to Potentially Rebound after Yesterday's 7.11% Sell Off

Stemline Therape (NASDAQ:STML) traded in a range yesterday that spanned from a low of $9.28 to a high of $9.28. Yesterday, the shares fell 7.1%, which took the trading range below the 3-day low of $9.68...

STML : 12.36 (-6.79%)
Shares of STML Down 29.6% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Stemline Therape (NASDAQ:STML) on October 15th, 2018 at $14.75. In approximately 3 months, Stemline Therape has returned 29.63% as of today's recent price of $10.38....

STML : 12.36 (-6.79%)
Stemline Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

Stemline Therapeutics, Inc. (NASDAQ:STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that Ivan Bergstein, M.D., Stemline's...

JPM : 99.75 (-3.03%)
STML : 12.36 (-6.79%)
Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal

It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.

AGEN : 2.83 (-5.03%)
STML : 12.36 (-6.79%)
GILD : 63.77 (-1.77%)
ACOR : 13.14 (-6.48%)
SRRK : 18.66 (-3.22%)

Van Meerten Stock Picks

Trilogy Metals - Pick of the Day
My Stock Pick of the Day belongs metal mining company Trilogy Metals(TMQ).
TMQ -0.18
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar